Saturation toxicokinetics of thioacetamide: role in initiation of liver injury.
Thioacetamide (TA), a potent centrilobular hepatotoxicant, undergoes a two-step bioactivation mediated by microsomal CYP2E1 to TA sulfoxide (TASO), and further to TA-S,S-dioxide (TASO2), a reactive metabolite that initiates cellular necrosis. Our earlier studies showed that bioactivation-mediated liver injury of TA is not dose-proportional. The objective of this study was to examine whether increasing doses of TA lead to enzyme saturation, thereby resulting in lack of dose-response for injury: bioactivation of TA --> TASO --> TASO2 may follow zero-order kinetics. A 12-fold dose range of TA (50, 300, and 600 mg/kg i.p.) was injected into male Sprague-Dawley rats. TA and TASO were quantified in plasma, liver, and urine by high-performance liquid chromatography. With increasing doses, the apparent elimination half-lives of TA and TASO increased linearly, indicating that TA bioactivation exhibits saturation kinetics. Increasing TA dose resulted in greater-than-proportional increases in plasma TA and TASO levels. The TASO/TA ratio was inversely proportional to the dose of TA. Covalent binding of 14C-TA-derived radiolabel to liver macromolecules showed a less-than-dose-proportionate increase with a 12-fold higher dose. Less than dose-proportional covalent binding was confirmed in liver microsomal incubations with 14C-TA. Three-fold higher excretion of TASO was seen in urine at the highest dose (600 mg/kg) compared with the lowest dose (50 mg TA/kg). Incubation of TA with rat liver microsomes and purified baculovirus-expressed rat and human CYP2E1 Supersomes, over a concentration range of 0.01 to 10 mM, revealed saturation of TA conversion to TASO at and above 0.05 mM TA concentration, comparable to in vivo plasma and liver levels achieved upon administration of higher doses. Calculated K(m) values for TA (0.1 mM) and TASO (0.6 mM) suggest that the second step of TA bioactivation is 6-fold less efficient. Collectively, the findings indicate saturation of CYP2E1 at the first (TA to TASO) and second (TASO to TASO2) steps of TA bioactivation.
Chilakapati
Jaya
J
Department of Toxicology, College of Pharmacy, The University of Louisiana Monroe, 700 University Avenue, Sugar Hall 306, Monroe, Louisiana 71209-0470, USA.
Shankar
Kartik
K
Korrapati
Midhun C
MC
Hill
Ronald A
RA
Mehendale
Harihara M
HM
D000818:Animals; D001798:Blood Proteins / Q000378:metabolism; D019392:Cytochrome P-450 CYP2E1 / Q000502:physiology; D007668:Kidney / Q000378:metabolism; D008099:Liver / Q000187:drug effects*; D008297:Male; D008862:Microsomes, Liver / Q000378:metabolism; D011485:Protein Binding; D051381:Rats; D017207:Rats, Sprague-Dawley; D013454:Sulfoxides / Q000378:metabolism; D013853:Thioacetamide / Q000493:pharmacokinetics* / Q000633:toxicity*
D001798:Blood Proteins; D013454:Sulfoxides; D013853:Thioacetamide; D019392:Cytochrome P-450 CYP2E1